Tetrahydroisoquinoline reduces angiogenesis by interacting myeloma cells with HUVECs mediated by extracellular vesicles.
Humans
Human Umbilical Vein Endothelial Cells
/ drug effects
Multiple Myeloma
/ pathology
Extracellular Vesicles
/ metabolism
Neovascularization, Pathologic
/ drug therapy
Tetrahydroisoquinolines
/ pharmacology
Cell Movement
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Coculture Techniques
Angiogenesis Inhibitors
/ pharmacology
Angiogenesis
Angiogenesis
Extracellular vesicles (EVs)
IL-6
Multiple myeloma (MM)
Tetrahydroisoquinoline (THIQ)
Vascular endothelial growth factor receptor 2 (VEGFR-2)
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
05 Aug 2024
05 Aug 2024
Historique:
received:
14
06
2024
accepted:
26
07
2024
medline:
5
8
2024
pubmed:
5
8
2024
entrez:
5
8
2024
Statut:
epublish
Résumé
Multiple myeloma (MM) is a neoplastic condition resulting from the uncontrolled expansion of B-cell-derived plasma cells. The importance of angiogenesis in MM development has also been demonstrated. Extracellular vesicles (EVs) have vital functions in interactions between neighboring cells, such as angiogenesis. The objective of this in vitro study was to examine the transfection and angiogenesis effects of MM-EVs on endothelial cells (ECs) upon treatment with Tetrahydroisoquinoline (THIQ) as a bioactive organic compound derivative from isoquinoline. Following treatment of multiple myeloma cells (U266) with THIQ, MM-EVs were harvested and transmigrated to human umbilical vein endothelial cells (HUVEC) in a co-culture model. EVs transmigration was traced by flow cytometry. Correspondingly, the expression of angiogenic genes and/or proteins in U266 cells and HUVECs was measured by RT-PCR and ELISA methods. Likewise, the proliferation and migration of HUVECs treated with THIQ-treated MM-EVs were visualized and estimated by performing both tube formation and scratch wound healing methods. Surprisingly, the anti-angiogenic effect of THIQ-treated MM-EVs was evident by the decreased expression of CD34, VEGFR2, and IL-6 at the mRNA and/or protein levels after internalization of MM-EVs in HUVEC. Finally, tube formation and scratch wound healing experiments showed inhibition of HUVEC cell proliferation and migration by THIQ-treated MM-EVs compared to control MM-EVs. MM-EVs derived from THIQ-treated myeloma cells (U266) inhibited angiogenesis in HUVECs. This phenomenon is coordinated by the internalized THIQ-treated MM-EVs in HUVECs, and ultimately the reduction of angiogenic factors and inhibition of tube formation and scratch wound healing.
Identifiants
pubmed: 39102060
doi: 10.1007/s12032-024-02465-8
pii: 10.1007/s12032-024-02465-8
doi:
Substances chimiques
Tetrahydroisoquinolines
0
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
217Subventions
Organisme : Iran University of Medical Sciences
ID : 99-3-5-19468
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Huang J, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9(9):e670–7.
doi: 10.1016/S2352-3026(22)00165-X
pubmed: 35843248
Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol. 2011;6:249–74.
doi: 10.1146/annurev-pathol-011110-130249
pubmed: 21261519
ME, J.F., et al., 2024 Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2015;385(9983):2197–208.
doi: 10.1016/S0140-6736(14)60493-1
pubmed: 25540889
Alanazi F, et al. New generation drugs for treatment of multiple myeloma. Drug Discovery Today. 2020;25(2):367–79.
doi: 10.1016/j.drudis.2019.11.008
pubmed: 31765717
Saltarella I, et al. Anti-Angiogenic Activity of Drugs in Multiple Myeloma. Cancers. 2023;15(7):1990.
doi: 10.3390/cancers15071990
pubmed: 37046651
pmcid: 10093708
Gkotzamanidou M, et al. Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma. Med Sci Monit Int Med J Exp Clin Res. 2013;19:1188.
Lamanuzzi A, et al. Thrombopoietin promotes angiogenesis and disease progression in patients with multiple myeloma. Am J Pathol. 2021;191(4):748–58.
doi: 10.1016/j.ajpath.2020.12.016
pubmed: 33516787
Liu Y, et al. Microvesicles secreted from human multiple myeloma cells promote angiogenesis. Acta Pharmacol Sin. 2014;35(2):230–8.
doi: 10.1038/aps.2013.141
pubmed: 24374814
Anderson JD, et al. Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of Angiogenesis via nuclear factor-KappaB signaling. Stem Cells. 2016;34(3):601–13.
doi: 10.1002/stem.2298
pubmed: 26782178
Lau NCH, Yam JWP. From exosome biogenesis to absorption: key takeaways for cancer research. Cancers. 2023;15(7):1992.
doi: 10.3390/cancers15071992
pubmed: 37046653
pmcid: 10093369
Guo HM, et al. Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro. Oncol Rep. 2018;39(6):2873–80.
pubmed: 29693175
Siemerink MJ, et al. CD34 marks angiogenic tip cells in human vascular endothelial cell cultures. Angiogenesis. 2012;15:151–63.
doi: 10.1007/s10456-011-9251-z
pubmed: 22249946
pmcid: 3274677
Shahidi M, et al. Endothelial tip cell formation induced by chronic lymphocytic leukemia plasma (JAK2 positivity amplified this effect). J Hematop. 2017;10:9–15.
doi: 10.1007/s12308-017-0291-1
Singh IP, Shah P. Tetrahydroisoquinolines in therapeutics: a patent review (2010–2015). Expert Opin Ther Pat. 2017;27(1):17–36.
doi: 10.1080/13543776.2017.1236084
pubmed: 27623022
Scott JD, Williams RM. Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics. Chem Rev. 2002;102(5):1669–730.
doi: 10.1021/cr010212u
pubmed: 11996547
Kandinska MI, et al. Synthesis of Novel 1-Oxo-2, 3, 4-trisubstituted tetrahydroisoquinoline derivatives, bearing other heterocyclic moieties and comparative preliminary study of anti-coronavirus activity of selected compounds. Molecules. 2023;28(3):1495.
doi: 10.3390/molecules28031495
pubmed: 36771170
pmcid: 9921785
Fang Y, et al. Synthesis and evaluation of tetrahydroisoquinoline-benzimidazole hybrids as multifunctional agents for the treatment of Alzheimer’s disease. Eur J Med Chem. 2019;167:133–45.
doi: 10.1016/j.ejmech.2019.02.008
pubmed: 30771601
Chrzanowska M, Grajewska A, Rozwadowska MD. Diastereoselective synthesis of (–)-6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinoline-1-carboxylic acid via morpholinone derivatives. Molecules. 2023;28(7):3200.
doi: 10.3390/molecules28073200
pubmed: 37049962
pmcid: 10095930
Gangapuram M, et al. Design and synthesis of tetrahydroisoquinoline derivatives as anti-angiogenesis and anti-cancer agents. Anticancer Agents Med Chem. 2021;21(18):2505–11.
doi: 10.2174/1871520621666210112122913
pubmed: 33438560
pmcid: 8694809
Huang Y, et al. Design, synthesis, and biological evaluation of tetrahydroisoquinoline-based diaryl urea derivatives for suppressing VEGFR-2 signaling. Anticancer Drugs. 2019;30(5):508–16.
doi: 10.1097/CAD.0000000000000718
pubmed: 30531369
Bernimoulin M, et al. Differential stimulation of monocytic cells results in distinct populations of microparticles. J Thromb Haemost. 2009;7(6):1019–28.
doi: 10.1111/j.1538-7836.2009.03434.x
pubmed: 19548909
pmcid: 3242443
Atmaca H, Uzunoglu S. Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells. Eur Cytokine Netw. 2014;25(1):1–7.
doi: 10.1684/ecn.2014.0347
pubmed: 24941346
Thompson CA, et al. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem. 2013;288(14):10093–9.
doi: 10.1074/jbc.C112.444562
pubmed: 23430739
pmcid: 3617250
Roccaro AM, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013;123(4):1542–55.
doi: 10.1172/JCI66517
pubmed: 23454749
pmcid: 3613927
Shimma N, et al. Possible role of interleukin-6 in PC12 cell death induced by MPP+ and tetrahydroisoquinoline. J Pharmacol Sci. 2003;93(4):471–7.
doi: 10.1254/jphs.93.471
pubmed: 14737019
Zhang B, et al. Human umbilical cord mesenchymal stem cell exosomes enhance angiogenesis through the Wnt4/β-catenin pathway. Stem Cells Transl Med. 2015;4(5):513–22.
doi: 10.5966/sctm.2014-0267
pubmed: 25824139
pmcid: 4414225
Shabbir A, et al. Mesenchymal stem cell exosomes induce proliferation and migration of normal and chronic wound fibroblasts, and enhance angiogenesis in vitro. Stem Cells Dev. 2015;24(14):1635–47.
doi: 10.1089/scd.2014.0316
pubmed: 25867197
pmcid: 4499790
Choi Y-C, et al. Regulation of vascular endothelial growth factor signaling by miR-200b. Mol Cells. 2011;32:77–82.
doi: 10.1007/s10059-011-1042-2
pubmed: 21544626
pmcid: 3887663
Chen Y, Zhou X, Wu Y. The miR-26a-5p/IL-6 axis alleviates sepsis-induced acute kidney injury by inhibiting renal inflammation. Ren Fail. 2022;44(1):551–61.
doi: 10.1080/0886022X.2022.2056486
pubmed: 35491874
pmcid: 9067948
Zanoaga O, et al. The role of miR-155 in nutrition: modulating cancer-associated inflammation. Nutrients. 2021;13(7):2245.
doi: 10.3390/nu13072245
pubmed: 34210046
pmcid: 8308226
Gao J, et al. Tumor endothelial cell-derived extracellular vesicles contribute to tumor microenvironment remodeling. Cell Commun Signal. 2022;20(1):97.
doi: 10.1186/s12964-022-00904-5
pubmed: 35752798
pmcid: 9233793
Sim S, et al. Design, synthesis, and biological evaluation of potent 1, 2, 3, 4-tetrahydroisoquinoline derivatives as anticancer agents targeting NF-κB signaling pathway. Bioorg Med Chem. 2021;46:116371.
doi: 10.1016/j.bmc.2021.116371
pubmed: 34500188
Pan J, et al. Extracellular vesicles derived from glioblastoma promote proliferation and migration of neural progenitor cells via PI3K-Akt pathway. Cell Commun Signal. 2022;20(1):7.
doi: 10.1186/s12964-021-00760-9
pubmed: 35022057
pmcid: 8756733
Cao F-J, et al. Effects of 2-aryl-1-cyano-1, 2, 3, 4-tetrohydroisoquinolines on apoptosis induction mechanism in NB4 and MKN-45 cells. Toxicol In Vitro. 2019;54:295–303.
doi: 10.1016/j.tiv.2018.10.007
pubmed: 30342220
Qian Z, et al. The role of extracellular vesicles: an epigenetic view of the cancer microenvironment. Biomed Res Int. 2015;2015(1):649161.
pubmed: 26582468
pmcid: 4637039
Chen D, et al. Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer. Acta pharmaceutica sinica B. 2016;6(1):93–9.
doi: 10.1016/j.apsb.2015.11.002
pubmed: 26904403
pmcid: 4724696
Shao J, et al. Discovery of 2-substituted-N-(3-(3, 4-dihydroisoquinolin-2 (1H)-yl)-2-hydroxypropyl)-1, 2, 3, 4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation. Eur J Med Chem. 2019;164:317–33.
doi: 10.1016/j.ejmech.2018.12.065
pubmed: 30605830
Batagov AO, Kurochkin IV. Exosomes secreted by human cells transport largely mRNA fragments that are enriched in the 3′-untranslated regions. Biol Direct. 2013;8:1–8.
doi: 10.1186/1745-6150-8-12